お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:DEL (DNA-Encoded Library):プラットフォーム&サービス市場
市場調査レポート
商品コード
919315

DEL (DNA-Encoded Library):プラットフォーム&サービス市場

DNA-Encoded Libraries: Platforms and Services Market

出版日: | 発行: Roots Analysis | ページ情報: 英文 133 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.81円
DEL (DNA-Encoded Library):プラットフォーム&サービス市場
出版日: 2020年01月31日
発行: Roots Analysis
ページ情報: 英文 133 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

創薬プロセスに伴う複雑さから、医薬品・バイオテクノロジー部門のR&D支出は年々増加しており、2019年のR&D費は約1820億米ドルと推計されています。DEL (DNA-Encoded Library) はライブラリサイズ、コスト、機器のニーズなどの点でハイスループットスクリーニングに勝ることから、大量の低分子化合物の合成およびスクリーニングのための高度な併用薬創薬ツールであることが実証されています。

当レポートでは、DEL (DNA-Encoded Library) プラットフォームおよびサービスの市場を調査し、創薬プロセス、DELの概要、発展の経緯、メリット・デメリット、関連事業者の分布、主要企業のプロファイル、企業間提携の動向、ケーススタディ、医薬大手によるイニシアチブ、市場規模の推移・予測などをまとめています。

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 本章の概要
  • 薬剤開発の概要
  • 創薬プロセス
    • 標的同定
    • 標的バリデーション
    • ヒット生成
      • ハイスループットスクリーニング
      • フラグメントスクリーニング
      • バーチャルスクリーニング
      • DEL (DNA-Encoded Library) スクリーニング
    • HTL (Hit-to-Lead)
    • リード最適化
  • DELの概要
    • 発展の経緯
    • ライブラリ構築のエンコーディング戦略
    • 従来型ライブラリ・DELの比較
    • 主なメリット
    • 課題・制約
  • 将来の展望・市場機会のエリア

第4章 現在の市場環境

  • 本章の概要
  • DEL:総市場
    • ライブラリサイズ別
    • 薬理学的リード別
    • ライブラリ合成手法別
    • 治療標的別
    • 治療エリア別
  • DEL:ディベロッパー環境
    • 設立年別
    • 企業規模別
    • 所在地別
    • 提供サービス別
  • DEL:サポート企業

第5章 提携・協力

  • 本章の概要
  • 提携モデル
  • DEL:近年の提携・協力
    • 提携年別
    • 提携タイプ別
    • 提携年・パートナータイプ別
    • もっとも活発な事業者
    • もっとも人気のDEL
    • 地域分析

第6章 企業プロファイル

  • 本章の概要
  • HitGen
  • X-Chem
  • Vipergen
  • DyNAbind

第7章 ケーススタディ:DELを用いた生物学的標的

  • 本章の概要
  • 癌のアンドラッガブル標的
    • GPCR
    • GPCR標的薬:臨床・前臨床段階の分子リスト
  • DNA修復標的
    • PARP阻害剤:概要
    • PARP阻害剤:臨床・前臨床段階の分子リスト
  • その他の標的

第8章 医薬大手によるイニチアチブ

  • 本章の概要
  • 主要企業
  • Amgen
  • AstraZeneca
  • GSK
  • Novartis
  • Pfizer
  • Roche

第9章 DEL市場:市場機会の分析

  • 本章の概要
  • 前提因子
  • 予測手法
  • DELライセンシング市場:前払い金・マイルストーン金
  • DEL市場:新たな市場機会

第10章 総論

第11章 専門家による見解

第12章 付録 1:図表

第13章 付録 2:企業・組織リスト

図表

List Of Figures

  • Figure 3.1. Drug Discovery and Development Timeline
  • Figure 3.2. Drug Discovery Process
  • Figure 3.3. Concept of DNA-Encoded Libraries
  • Figure 3.4. Historical Evolution of DNA-Encoded Libraries
  • Figure 3.5. Encoding Strategies for Constructing DNA-Encoded Libraries
  • Figure 3.6. Comparison of Traditional Libraries and DNA-Encoded Libraries
  • Figure 3.7. Advantages of DNA-Encoded Libraries
  • Figure 3.8. Limitations of DNA-Encoded Libraries
  • Figure 4.1. DNA-Encoded Libraries: Distribution by Library Size
  • Figure 4.2. DNA-Encoded Libraries: Distribution by Type of Pharmacological Lead
  • Figure 4.3. DNA-Encoded Libraries: Distribution by Method of Library Synthesis
  • Figure 4.4. DNA-Encoded Libraries: Distribution by Therapeutic Target
  • Figure 4.5. DNA-Encoded Libraries: Distribution by Therapeutic Area
  • Figure 4.6. DNA-Encoded Libraries: Distribution by Year of Establishment
  • Figure 4.7. DNA-Encoded Libraries: Distribution by Company Size
  • Figure 4.8. DNA-Encoded Libraries: Distribution by Geographical Location
  • Figure 4.9. DNA-Encoded Libraries: Distribution by Year of Establishment, Company Size and Geographical Location
  • Figure 4.10. DNA-Encoded Libraries: Distribution by Type of Service Offered
  • Figure 4.11. DNA-Encoded Libraries: Geographical Landscape of Developers by Type of Service Offering
  • Figure 5.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2010-2019 (till October)
  • Figure 5.2. Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 5.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership
  • Figure 5.4. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Figure 5.5. Most Active Players: Distribution by Number of Partnerships
  • Figure 5.6. Most Popular Technologies: Distribution by Number of Partnerships
  • Figure 5.7. Most Active Players: Geographical Distribution by Number of Partnerships
  • Figure 5.8. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 6.1. HitGen: Service Portfolio
  • Figure 6.2. HitGen: DNA-Encoded Library Synthesis
  • Figure 6.3. HitGen: DNA-Encoded Library Steps
  • Figure 6.4. X-Chem: DNA-Encoded Library Synthesis
  • Figure 6.5. Vipergen: Service Portfolio
  • Figure 6.6. Vipergen: DNA-Encoded Library Synthesis
  • Figure 6.7. Vipergen: MedChem HTS versus YoctoReactor
  • Figure 6.8. DyNAbind: Service Portfolio
  • Figure 8.1. Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
  • Figure 9.1. Licensing Agreements: Distribution of Financial Components
  • Figure 9.2. Library Licensing Deal: Payment Structure
  • Figure 9.3. DNA-Encoded Libraries: Platforms and Services Market: Upfront and Milestone Payments, 2020, 2025 and 2030 (USD Million)
  • Figure 9.4. Case Study: Popular Drug Discovery Methods, 2016-2017

List Of Tables

  • Table 4.1. DNA-Encoded Libraries: Technology Overview
  • Table 4.2. DNA-Encoded Libraries: Methods of Library Synthesis
  • Table 4.3. DNA-Encoded Libraries: Developer Overview
  • Table 4.4. DNA-Encoded Libraries: Type of Service Offered
  • Table 4.5. DNA-Encoded Libraries: Supporting Companies
  • Table 5.1. DNA-Encoded Libraries: Partnerships and Collaborations, 2010-2019
  • Table 6.1. HitGen: Key Highlights
  • Table 6.2. HitGen: Recent Developments and Future Outlook
  • Table 6.3. X-Chem: Company Snapshot
  • Table 6.4. X-Chem: Recent Developments and Future Outlook
  • Table 6.5. Vipergen: Company Snapshot
  • Table 6.6. Vipergen: Recent Developments and Future Outlook
  • Table 6.7. DyNAbind: Company Snapshot
  • Table 6.8. DyNAbind: Recent Developments and Future Outlook
  • Table 7.1. GPCR's: List of Clinical / Preclinical Molecules
  • Table 7.2. PARP Inhibitors: List of Clinical / Preclinical Molecules
  • Table 8.1. Amgen: Company Snapshot
  • Table 8.2. AstraZeneca: Company Snapshot
  • Table 8.3. GSK: Company Snapshot
  • Table 8.4. Novartis: Company Snapshot
  • Table 8.5. Pfizer: Company Snapshot
  • Table 8.6. Roche: Company Snapshot
  • Table 9.1. Library Licensing Deal: Tranches of Milestone Payments
  • Table 9.2. DNA-Encoded Libraries: Average Upfront Payments and Average Milestone Payments (USD Million)
  • Table 10.1. DNA-Encoded Libraries: Summary of the Competitive Insights
  • Table 12.1. DNA-Encoded Libraries: Distribution by Library Size
  • Table 12.2. DNA-Encoded Libraries: Distribution by Type of Pharmacological Lead
  • Table 12.3. DNA-Encoded Libraries: Distribution by Method of Library Synthesis
  • Table 12.4. DNA-Encoded Libraries: Distribution by Therapeutic Target
  • Table 12.5. DNA-Encoded Libraries: Distribution by Therapeutic Area
  • Table 12.6. DNA-Encoded Libraries: Distribution by Year of Establishment
  • Table 12.7. DNA-Encoded Libraries: Distribution by Company Size
  • Table 12.8. DNA-Encoded Libraries: Distribution by Geographical Location
  • Table 12.9. DNA-Encoded Libraries: Distribution by Type of Service Offered
  • Table 12.10. Partnerships and Collaborations: Cumulative Year-wise Trend, 2010-2019
  • Table 12.11. Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 12.12. Partnerships and Collaborations: Year-wise Trend by Type of Partnership
  • Table 12.13. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Table 12.14. Partnerships and Collaborations: Most Active Players
  • Table 12.15. Most Popular Technologies: Distribution by Number of Partnerships
  • Table 12.16. Partnerships and Collaborations: Analysis by Local and International Distribution
  • Table 12.17. DNA-Encoded Libraries: Platforms and Services Market: Upfront and Milestone Payments, 2020, 2025 and 2030 (USD Million)
  • Table 12.18. Case Study: Popular Drug Discovery Methods, 2016-2017

Listed Companies

The following companies and organizations have been mentioned in the report.

  • 1. AbbVie
  • 2. Abilita Bio
  • 3. Actelion Pharmaceuticals
  • 4. Aduro Biotech
  • 5. Alexion Pharmaceuticals
  • 6. Almirall
  • 7. Amgen
  • 8. AMRI
  • 9. Arvinas
  • 10. Asinex
  • 11. Astellas Pharma
  • 12. AstraZeneca
  • 13. BASF
  • 14. Bayer
  • 15. BeiGene
  • 16. Biogen
  • 17. Biokine Therapeutics
  • 18. BioLineRx
  • 19. Biotage
  • 20. Bristol-Myers Squibb
  • 21. BOC Sciences
  • 22. Boehringer Ingelheim
  • 23. Broad Institute
  • 24. California Institute for Biomedical Research (Calibr)
  • 25. Cancer Research Technology
  • 26. Cantex Pharmaceuticals
  • 27. Central European Institute of Technology (CEITEC)
  • 28. Charles River Laboratories
  • 29. Checkpoint Therapeutics
  • 30. ChemAxon
  • 31. ChemRoutes
  • 32. Chem-Space
  • 33. Circle Pharma
  • 34. Clovis Oncology
  • 35. Cocrystal Pharma
  • 36. Columbia University
  • 37. ComInnex
  • 38. Confo Therapeutics
  • 39. Cyclofluidic
  • 40. Daiichi Sankyo
  • 41. DELopen
  • 42. Deluge Biotechnologies
  • 43. DiCE Molecules
  • 44. DNA Technologies and Expression Analysis Core, University of California
  • 45. DyNAbind
  • 46. Edelris
  • 47. Eli Lilly
  • 48. Enamine
  • 49. Ensemble Therapeutics
  • 50. ETH Zurich
  • 51. Exo therapeutics
  • 52. FORMA Therapeutics
  • 53. Galapagos
  • 54. Genentech
  • 55. Gilead Sciences
  • 56. Global Blood Therapeutics
  • 57. GlycoMimetics
  • 58. Heptares Therapeutics
  • 59. HitGen
  • 60. HotSpot Therapeutics
  • 61. InterX Technologies
  • 62. Janssen Biotech
  • 63. Jeil Pharmaceutical
  • 64. Jiangsu Hengrui Medicine
  • 65. Johnson & Johnson
  • 66. Kymera Therapeutics
  • 67. LEO Pharma
  • 68. Liverpool ChiroChem
  • 69. LG Chem
  • 70. LGC, Bioresearch Technologies
  • 71. Macroceutics
  • 72. Maruho
  • 73. MD Anderson Cancer Center
  • 74. Medivation
  • 75. Merck
  • 76. Mitsubishi Tanabe Pharma
  • 77. Navitor Pharmaceuticals
  • 78. NetVation
  • 79. Northwestern University
  • 80. Novartis
  • 81. Nuevolution
  • 82. Nurix Therapeutics
  • 83. OMass Therapeutics
  • 84. Ono Pharmaceutical
  • 85. Orbit Discovery
  • 86. Otsuka Pharmaceutical
  • 87. Pfizer
  • 88. Pharmaceutical Product Development
  • 89. Pharmaron
  • 90. Philochem
  • 91. PhoreMost
  • 92. PhyNexus
  • 93. Plexium
  • 94. Polyphor
  • 95. Praecis Pharmaceuticals
  • 96. PROvendis
  • 97. PsyBrain
  • 98. Radikal Therapeutics
  • 99. Roche
  • 100. Sanofi
  • 101. Servier
  • 102. Simcere Pharmaceutical
  • 103. Sun Pharma Advanced Research Company (SPARC)
  • 104. SpiroChem
  • 105. Taiho Pharmaceutical
  • 106. Takeda Pharmaceutical
  • 107. Tasly
  • 108. Tesaro
  • 109. The Scripps Research Institute
  • 110. University of California
  • 111. University of Manchester
  • 112. University of Pennsylvania
  • 113. Vertex Pharmaceuticals
  • 114. Vipergen
  • 115. Viva Biotech
  • 116. Warp Drive Bio
  • 117. WuXi AppTec
  • 118. X-Biotix Therapeutics
  • 119. X-Chem
  • 120. X4 Pharmaceuticals
目次

Example Insights:

In the short term, the opportunity is likely to be driven by library platform licensing activity; this activity is likely to increase as the industry realizes the capability of DNA-encoded libraries to discover high-value therapeutic leads.

Overview:

The process of drug development, beginning from the discovery of a molecule to its commercial launch, takes around 10-15 years and capital investments worth USD 4-10 billion. It is a well-known fact that only a small proportion of molecules, which are selected for further investigation during the initial stages of research, are actually translated into product candidates. Given the complexities involved in the drug discovery process, the overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector has steadily increased over time. Specifically, in 2019, the R&D spending was estimated to be around USD 182 billion; over 16,000 drug molecules were reportedly evaluated during the year. The industry is presently under tremendous pressure not only to identify ways to mitigate the risks of failure of drug discovery programs but also to meet the expectations of a growing patient population.

DNA-encoded libraries (also known as DELs), owing to their advantages (such as library size, cost and equipment needs) over high-throughput screening, have demonstrated to be a sophisticated combinatorial drug discovery tool for synthesis and screening of large collections of small molecule compounds. Interestingly, DNA-encoded libraries encompassing as high as 40 trillion different molecules have been developed, enabling screening, hit identification and discovery of pharmacological leads (including macrocycles, natural products and small molecules) against undruggable and unique targets using a single library and accelerating the process of drug development. Moreover, introduction of automated screening of small organic ligands using DNA-encoded chemical libraries has enabled identification of potential lead molecules within a time duration of 10 days.

Several mid-sized to large companies have undertaken initiatives towards building in-house DNA-encoded library technology. In addition, players have forged strategic alliances with service providers for accessing the latter's DNA-encoded libraries for the purpose of drug discovery. The growing number of drug discovery projects, coupled to the rapid progression of molecules through various stages of drug discovery, is expected to continue to increase demand for such advanced drug discovery tools.

Scope of the Report:

The “DNA-Encoded Libraries: Platforms and Services Market” report features an extensive study of the current landscape and the untapped opportunities these DNA-encoded likely to bring in the field of drug discovery. In addition to other elements, the report includes:

  • An overview of the current market landscape of DNA-encoded libraries, featuring details on the type of pharmacological lead (macrocycles, natural products, peptides and small molecules), library size, method of library synthesis, type of therapeutic target and type of therapeutic area.
  • An overview of the landscape of DNA-encoded library developers and analysis based on parameters, such as year of establishment, company size, type of service offered (screening service / hit identification, hit optimization / validation, custom library design / synthesis, in-house drug development and DNA-encoded library service kits) and geographical location.
  • A detailed analysis of the partnerships related to DNA-encoded libraries, which have been established in the recent past, covering research collaborations, research and development agreements, licensing agreements, acquisitions, distribution agreements, service alliances, and other relevant agreements.
  • Elaborate profiles of the prominent service providers engaged in this domain. Each profile features a brief overview of the company, information on its service portfolio, DNA-encoded library portfolio, recent developments and an informed future outlook.
  • A brief overview of the initiatives taken by big pharma companies (such as Amgen, AstraZeneca, GSK, Novartis, Pfizer and Roche) involved in this domain, highlighting the key focus areas of these players along with information on the recent deals inked with the DNA-encoded library providers (if available) . It also features company snapshots for each of the above-mentioned companies

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. It presents a high-level view on the current scenario within the DNA-encoded libraries developers' market and its evolution in the short-mid-term and long term.

Chapter 3 provides an introduction to the process of drug discovery and development. In addition, the chapter focuses on the concept of DNA-encoded libraries with information on the evolution of these libraries, advantages over other conventional drug discovery methods and the challenges associated with the same. It also features a brief discussion on the opportunities and the likely future trends in this field.

Chapter 4 provides a detailed overview of the current market landscape of DNA-encoded libraries, featuring information on type of pharmacological lead (macrocycles, natural products, peptides and small molecules), library size, method of library synthesis, type of therapeutic target and type of therapeutic area. In addition, the chapter provides an overview of DNA-encoded libraries developers and analysis based on parameters, such as year of establishment, company size, type of service offered (screening service / hit identification, hit optimization / validation, custom library design / synthesis, in-house drug development and DNA-encoded library service kits) and geographical location.

Chapter 5 features an in-depth analysis and discussion on the various collaborations and partnerships inked between the players in the recent past; these include research collaborations, research and development agreements, licensing agreements, acquisitions, distribution agreements, service alliances, and other relevant agreements.

Chapter 6 provides detailed profiles of the prominent service providers engaged in this domain. Each profile features a brief overview of company, information on its services associated with their DNA-Encoded library, recent developments and an informed future outlook.

Chapter 7 presents a case study on the therapeutic target(s) against which the DNA-encoded libraries are capable of identifying potential leads. Examples of such targets include undruggable cancer targets (special focus on GPCRs) , DNA repair targets (special focus on PARP inhibitors) and other targets (such as alpha-1-acid glycoprotein (AGP), carbonic anhydrase IX, mitogen-activated protein kinase 14 (MAPK14), Neurokinin 3 (NK3), receptor-interacting protein 1 kinase (RIP1), soluble epoxide hydrolase (sEH) and interleukin 2).

Chapter 8 presents overview of the initiatives taken by big pharma companies (such as Amgen, AstraZeneca, GSK, Novartis, Pfizer and Roche) involved in this domain, highlighting the key focus areas of these players along with information on the recent deals inked with the DNA-encoded library providers (if available). It also features company snapshots for each of the above-mentioned companies.

Chapter 9 presents an insightful market forecast analysis, highlighting likely growth of DNA-encoded libraries market till the year 2030, on the basis of likely licensing deal structures and agreements that are expected to be signed in the foreseen future.

Chapter 10 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it highlights the various evolutionary trends that are likely to determine the future of the DNA-encoded library screening approach.

Chapter 11 is a collection of interview transcripts of the discussions held with key stakeholders in this market.

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Drug Development
  • 3.3. Drug Discovery Process
    • 3.3.1. Target Identification
    • 3.3.2. Target Validation
    • 3.3.3. Hit Generation
      • 3.3.3.1. High-Throughput Screening
      • 3.3.3.2. Fragment Based Screening
      • 3.3.3.3. Virtual Screening
      • 3.3.3.4. DNA-Encoded Library-based Screening
    • 3.3.4. Hit-to-Lead
    • 3.3.5. Lead Optimization
  • 3.4. Overview of DNA-Encoded Libraries
    • 3.4.1. Historical Evolution
    • 3.4.2. Encoding Strategies for Library Construction
    • 3.4.3. Comparison of Traditional Libraries and DNA-Encoded Libraries
    • 3.4.4. Key Advantages
    • 3.4.5. Challenges and Limitations
  • 3.5. Future Perspectives and Opportunity Areas

4. CURRENT MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. DNA-Encoded Libraries: Overall Market Landscape
    • 4.2.1. Analysis by Library Size
    • 4.2.2. Analysis by Type of Pharmacological Lead
    • 4.2.3. Analysis by Method of Library Synthesis
    • 4.2.4. Analysis by Therapeutic Target
    • 4.2.5. Analysis by Therapeutic Area
  • 4.3. DNA-Encoded Libraries: Developer Landscape
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Geographical Location
    • 4.3.4. Analysis by Type of Service Offered
  • 4.4. DNA-Encoded Libraries: Supporting Companies

5. PARTNERSHIPS AND COLLABORATIONS

  • 5.1. Chapter Overview
  • 5.2. Partnership Models
  • 5.3. DNA-Encoded Libraries: Recent Partnerships and Collaborations
    • 5.3.1. Analysis by Year of Partnership
    • 5.3.2. Analysis by Type of Partnership
    • 5.3.3. Analysis by Year of Partnership and Type of Partner
    • 5.3.4. Most Active Players: Analysis by Number of Partnerships
    • 5.3.5. Most Popular DNA-Encoded Libraries: Analysis by Number of Partnerships
    • 5.3.6. Regional Analysis
      • 5.3.6.1. Most Active Players: Analysis by Local and International Agreements
      • 5.3.6.2. Intercontinental and Intracontinental Agreements

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. HitGen
    • 6.2.1. Company Overview
    • 6.2.2. Service Portfolio
      • 6.2.2.1. HitGen's DNA-Encoded Libraries
    • 6.2.3. Recent Developments and Future Outlook
  • 6.3. X-Chem
    • 6.3.1. Company Overview
    • 6.3.2. Service Portfolio
      • 6.3.2.1. X-Chem's DNA-Encoded Libraries
    • 6.3.3. Recent Developments and Future Outlook
  • 6.4. Vipergen
    • 6.4.1. Company Overview
    • 6.4.2. Service Portfolio
      • 6.4.2.1. Vipergen's DNA-Encoded Libraries
    • 6.4.3. Recent Developments and Future Outlook
  • 6.5. DyNAbind
    • 6.5.1. Company Overview
    • 6.5.2. Service Portfolio
      • 6.5.2.1. DyNAbind's DNA-Encoded Libraries
    • 6.5.3. Recent Developments and Future Outlook

7. CASE STUDY: LIKELY BIOLOGICAL TARGETS FOR DRUG DISCOVERY USING DNA-ENCODED LIBRARIES

  • 7.1. Chapter Overview
  • 7.2. Undruggable Cancer Targets
    • 7.2.1. G protein-coupled receptors (GPCRs)
    • 7.2.2. GPCRs Targeting Drugs: List of Clinical / Preclinical Molecules
  • 7.3. DNA Repair Targets
    • 7.3.1. poly ADP ribose polymerase (PARP) Inhibitors: Overview
    • 7.3.2. PARP Inhibitors: List of Clinical / Preclinical Molecules
  • 7.4. Other Targets

8. BIG PHARMA INITIATIVES: DNA-ENCODED LIBRARIES

  • 8.1. Chapter Overview
  • 8.2. Top Pharmaceutical Companies
  • 8.3. Amgen
    • 8.3.1. Company Snapshot
    • 8.3.2. Initiatives by Amgen
  • 8.4. AstraZeneca
    • 8.4.1. Company Snapshot
    • 8.4.2. Initiatives by AstraZeneca
  • 8.5. GSK
    • 8.5.1. Company Snapshot
    • 8.5.2. Initiatives by GSK
  • 8.6. Novartis
    • 8.6.1. Company Snapshot
    • 8.6.2. Initiatives by Novartis
  • 8.7. Pfizer
    • 8.7.1. Company Snapshot
    • 8.7.2. Initiatives by Pfizer
  • 8.8. Roche
    • 8.8.1. Company Snapshot
    • 8.8.2. Initiatives by Roche

9. DNA-ENCODED LIBRARY MARKET: OPPORTUNITY ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Key Assumptions and Input Data
  • 9.3. Forecast Methodology
  • 9.4. DNA-Encoded Libraries Licensing Market: Upfront and Milestone Payments, 2020, 2025 And 2030
  • 9.5. DNA-Encoded Libraries Market: Additional Opportunity

10. CONCLUDING REMARKS

  • 10.1. Chapter Overview
  • 10.2. Key Takeaways

11. EXECUTIVE INSIGHTS

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.